Portola Announces Data Showing Its Anti-Platelet Drug Inhibits Platelets In Clopidogrel (Plavix(R)) Non-Responders
Medical News Today
13th November 2008
Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, announced new clinical data that demonstrate PRT060128, the Company's novel anti-platelet drug that directly and reversibly inhibits the P2Y12 ADP receptor, overcomes high platelet reactivity (HPR) in patients who do not respond to clopidogrel (Plavix(R)). The results [Abstract #5603] were presented at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans, LA.
13th November 2008
Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, announced new clinical data that demonstrate PRT060128, the Company's novel anti-platelet drug that directly and reversibly inhibits the P2Y12 ADP receptor, overcomes high platelet reactivity (HPR) in patients who do not respond to clopidogrel (Plavix(R)). The results [Abstract #5603] were presented at the American Heart Association (AHA) Scientific Sessions 2008 in New Orleans, LA.
Latest news:
1st December 2008 -
Researchers Learn That Some 'Good Cholesterol' Isn't Good Enough
1st December 2008 -
New NPS Patient Resource On Infective Endocarditis, Australia
28th November 2008 -
Opportunity to invest in a novel Acoustic Pressure Sensor for medical applications
27th November 2008 -
International Medical Team Announces Patient Results In Adult Stem Cell Clinical Study For Pulmonary Hypertension
27th November 2008 -
Medis And TomTec Launch Joint Cardiac Imaging And Analysis Product
26th November 2008 -
Why Does It Take So Long For A Correct Diagnosis Of Pulmonary Hypertension?
26th November 2008 -
Dramatic JUPITER Findings Fail To Sway Prescribing Behavior, Poll Shows
15th November 2008 -
Statement By Merck & Co., Inc., In Response To The FDA's Update Regarding A Safety Review On Bisphosphonates Including FOSAMAX®
14th November 2008 -
Arsenic May Increase Risks For Cardiovascular Disease At Current Epa-Regulated Drinking Water Standards
14th November 2008 -
High-Normal Phosphate Levels Linked To Early Atherosclerosis
